Annexon, Inc. Cash Flow Statement
ANNX / Health Care|6 years of annual SEC 10-K data (FY2019-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 6 fiscal years. All figures from audited SEC 10-K filings.
Annexon, Inc. used $118M in operating cash flow and negative free cash flow of $118M in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Net Income | -$138.2M | -$134.2M | -$141.9M | -$130.3M | -$63.4M | -$37.2M |
| Depreciation & Amortization | $2.1M | $2.1M | $2.1M | $2.1M | $667.0K | $493.0K |
| Operating Cash Flow | -$118.0M | -$121.1M | -$116.3M | -$106.1M | -$53.1M | -$28.4M |
| Capital Expenditures | $15.0K | $193.0K | $6.5M | $1.7M | $464.0K | $267.0K |
| Free Cash Flow | -$118.0M | -$121.3M | -$122.8M | -$107.8M | -$53.6M | -$28.6M |